Advanced search
Publication Cover
Expert Review of Vaccines Volume 14, 2015 - Issue 12
Submit an article Journal homepage
881
Views
73
CrossRef citations to date
0
Altmetric
Reviews

Recent advances in developing vaccines against Toxoplasma gondii: an update

Nian-Zhang ZhangState Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, PR China
,
Meng WangState Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, PR China
,
Ying XuState Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, PR China;Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, National Animal Protozoa Laboratory, College of Veterinary Medicine, China Agricultural University, Beijing, PR China
,
Eskild PetersenDepartment of Infectious Diseases, Clinical Institute, Faculty of Health Sciences, Aarhus University, Aarhus, DenmarkCorrespondence[email protected] [email protected]
&
Xing-Quan ZhuState Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, PR ChinaCorrespondence[email protected] [email protected]
Pages 1609-1621 | Published online: 14 Oct 2015

References

** Describes new developments of the various vaccines against Toxoplasma gondii infection in cats, food-producing animals and mice

  • Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology. 1995;110:11–16.
  • Verma R, Khanna P. Development of Toxoplasma gondii vaccine: a global challenge. Hum Vaccin Immunother. 2013;9:291–293.
  • Cardona NI, Moncada DM, Gomez-Marin JE. A rational approach to select immunogenic peptides that induce IFN-γ response against Toxoplasma gondii in human leukocytes. Immunobiology. 2015 (in press).

** First to demonstrate an algorithm based on the principles of reverse vaccinology for human toxoplasmosis

  • Goodswen SJ, Kennedy PJ, Ellis JT. A novel strategy for classifying the output from an in silico vaccine discovery pipeline for eukaryotic pathogens using machine learning algorithms. BMC Bioinform. 2013;14:315.
  • Goodswen SJ, Kennedy PJ, Ellis JT. Enhancing in silico protein-based vaccine discovery for eukaryotic pathogens using predicted peptide-MHC binding and peptide conservation scores. PLoS One. 2014;9:e115745.
  • Wang HL, Li YQ, Yin LT, et al. Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis. PLoS One. 2013;8:e70884.
  • Wang HL, Pang M, Yin LT, et al. Intranasal immunisation of the recombinant Toxoplasma gondii receptor for activated C kinase 1 partly protects mice against T. gondii infection. Acta Trop. 2014;137:58–66.
  • Zhang NZ, Huang SY, Zhou DH, et al. Identification and bioinformatics analysis of a putative calcium-dependent protein kinase (CDPK6) from Toxoplasma gondii. Genet Mol Res. 2014;13:10669–10677.
  • Waldeland H, Frenkel JK. Live and killed vaccines against toxoplasmosis in mice. J Parasitol. 1983;69:60–65.
  • Zhao Y, Huang B, Huang S, et al. Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models. Parasitol Res. 2013;112:3151–3160.
  • Katzer F, Canton G, Burrells A, et al. Immunization of lambs with the S48 strain of Toxoplasma gondii reduces tissue cyst burden following oral challenge with a complete strain of the parasite. Vet Parasitol. 2014;205:46–56.
  • Burrells A, Benavides J, Cantón G, et al. Vaccination of pigs with the S48 strain of Toxoplasma gondii—safer meat for human consumption. Vet Res. 2015;46:47.
  • Fox BA, Bzik DJ. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature. 2002;415:926–929.
  • Fox BA, Bzik DJ. Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection. Infect Immun. 2015;83:2148–2155.

** First to evaluate the protective efficacy of nonreplicating, live-attenuated mutant strain based on ompdc and up genes deleted, which could induce a CD8+ T-cell-predominant immunity to prevent acute and chronic infections

  • Silveira C, Gargano N, Kijlstra A, et al. Toxoplasma vaccines: appropriate endpoints and sample size in future human clinical trials. Expert Rev Anti-Infect Ther. 2009;7:905–908.
  • Lu F, Huang S, Kasper LH. The temperature-sensitive mutants of Toxoplasma gondii and ocular toxoplasmosis. Vaccine. 2009;27:573–580.
  • Fox BA, Bzik DJ. Avirulent uracil auxotrophs based on disruption of orotidine-5ʹ-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun. 2010;78:3744–3752.
  • Hutson SL, Mui E, Kinsley K, et al. T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One. 2010;5:e14057.
  • Akbar H, Dimier-Poisson I, Moiré N. Role of CD4+ Foxp3+ regulatory T cells in protection induced by a live attenuated, replicating type I vaccine strain of Toxoplasma gondii. Infect Immun. 2015;83:3601–8611.
  • Lagal V, Dinis M, Cannella D, et al. AMA1-deficient Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity. Infect Immun. 2015;83:2475–2486.
  • Decoster A, Darcy F, Capron A. Recognition of Toxoplasma gondii excreted and secreted antigens by human sera from acquired and congenital toxoplasmosis: identification of markers of acute and chronic infection. Clin Exp Immunol. 1998;73:376–382.
  • Prigione I, Facchetti P, Lecordier L, et al. T cell clones raised from chronically infected healthy humans by stimulation with Toxoplasma gondii excretory—secretory antigens cross-react with live tachyzoites: characterization of the fine antigenic specificity of the clones and implications for vaccine development. J Immunol. 2000;164:3741–3748.
  • Garcia JL, Gennari SM, Navarro IT, et al. Partial protection against tissue cysts formation in pigs vaccinated with crude rhoptry proteins of Toxoplasma gondii. Vet Parasitol. 2005;129:209–217.
  • Daryani A, Sharif M, Kalani H, et al. Electrophoretic patterns of Toxoplasma gondii excreted secreted antigens and their role in induction of the humoral immune response. Jundishapur J Microbiol. 2014;7:e9525.
  • Tappeh KH, Khorshidvand Z, Shahabi S, et al. A novel adjuvant, mixture of alum and naltrexone, elicits humoral immune responses for excreted/secreted antigens of Toxoplasma gondii tachyzoites vaccine in Balb/c murine model. Turkiye Parazitol Derg. 2013;37:92–96.
  • Dimier-Poisson I, Carpentier R, N’Guyen TT, et al. Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials. 2015;50:164–175.
  • EL-Malky MA, Al-Harthi SA, Mohamed RT, et al. Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides comparison of immune responses in intranasal versus intramuscular administrations. Parasitol Res. 2014;113:2277–2284.
  • Abdollahi SH, Ayoobi F, Khorramdelazad H, et al Levels of transforming growth factor-beta after immunization of mice with in vivo prepared Toxoplasma gondii excretory/secretory proteins. Jundishapur J Microbiol. 2015;8:e17802.
  • Abdollahi SH, Ayoobi F, Khorramdelazad H, et al. Interleukin-10 serum levels after vaccination with in vivo prepared Toxoplasma gondii excreted/secreted antigens. Oman Med J. 2013;28:112–115.
  • Norouzpour Deilami K, Daryani A, Ahmadpour E, et al. Excretory-secretory antigens: a suitable candidate for immunization against ocular toxoplasmosis in a murine model. Comp Immunol Microbiol Infect Dis. 2014;37:369–374.
  • Wang Y, Zhang D, Wang G, et al. Immunization with excreted-secreted antigens reduces tissue cyst formation in pigs. Parasitol Res. 2013;112:3835–3842.
  • Lekutis C, Ferguson DJ, Grigg ME, et al. Surface antigens of Toxoplasma gondii: variations on a theme. Int J Parasitol. 2001;12:1285–1292.
  • Grzybowski MM, Dziadek B, Dziadek J, et al. Toxoplasma gondii: cloning, expression and immunoreactivity of recombinant ROP5 and ROP18 antigens. Exp Parasitol. 2015;150:1–6.
  • Chen J, Li ZY, Petersen E, et al. DNA vaccination with genes encoding Toxoplasma gondii antigens ROP5 and GRA15 induces protective immunity against toxoplasmosis in Kunming mice. Expert Rev Vaccines. 2015;14:617–624.
  • Zheng B, Lu S, Tong Q, et al. The virulence-related rhoptry protein 5 (ROP5) of Toxoplasma gondii is a novel vaccine candidate against toxoplasmosis in mice. Vaccine. 2013;31:4578–4584.
  • Lu G, Zhou A, Meng M, et al. Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii. BMC Infect Dis. 2014;14:3862.
  • Cong H, Zhang M, Xin Q, et al. Compound DNA vaccine encoding SAG1/SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii. Parasit Vectors. 2013;6:63.
  • Chuang SC, Ko JC, Chen CP, et al. Encapsulation of chimeric protein rSAG1/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against Toxoplasma gondii in mice. Exp Parasitol. 2013;134:430–437.
  • Mendes ÉA, Fonseca FG, Casério BM, et al. Recombinant vaccines against T. gondii comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1. PLoS One. 2013;8:e63201.
  • Chuang SC, Yang CD. Sustained release of recombinant surface antigen 2 (rSAG2) from poly(lactide-co-glycolide) microparticles extends protective cell-mediated immunity against Toxoplasma gondii in mice. Parasitology. 2014;18:1–10.
  • Albarracín RM, Becher ML, Farran I, et al. The fusion of Toxoplasma gondii SAG1 vaccine candidate to Leishmania infantum heat shock protein 83-kDa improves expression levels in tobacco chloroplasts. Biotechnol J. 2015;10:748–759.
  • Meng M, Zhou A, Lu G, et al. DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice. BMC Infect Dis. 2013;13:494.
  • EI Bissati K, Zhou Y, Dasgupta D, et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014;32:3243–3248.
  • Qu D, Han J, Du A. Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re. Exp Parasitol. 2013;135:234–239.
  • Wang HL, Zhang TE, Yin LT, et al. Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in mice. PLoS ONE. 2014;9:e108377.
  • Li XZ, Wang XH, Xia LJ, et al. Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice. BMC Infect Dis. 2015;15:114.
  • Parthasarathy S, Fong MY, Ramaswamy K, et al. Protective immune response in BALB/c mice induced by DNA vaccine of the ROP8 gene of Toxoplasma gondii. Am J Trop Med Hyg. 2013;88:883–887.
  • Chen J, Zhou DH, Li ZY, et al. Toxoplasma gondii protective immunity induced by rhoptry protein 9 (TgROP9). Exp Parasitol. 2014;139:42–48.
  • Yuan ZG, Ren D, Zhou DH, et al. Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic Toxoplasma gondii infection in a murine model. Vaccine. 2013;31:3135–3139.
  • Tao Q, Fang R, Zhang W, et al. Protective immunity induced by a DNA vaccine-encoding Toxoplasma gondii microneme protein 11 against acute toxoplasmosis in BALB/c mice. Parasitol Res. 2013;112:2871–2877.
  • Cong H, Yuan Q, Zhao Q, et al. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice. Parasit Vectors. 2014;7:145.
  • Liu Q, Wang F, Wang G, et al. Toxoplasma gondii immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2. Hum Vaccin Immunother. 2014;10:184–191.
  • Innes EA, Vermeulen AN. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora. Parasitology. 2006;133:S145–168.
  • Zhang M, Zhao L, Song J, et al. DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB/c mice against type II parasite infection. Vaccine. 2013;31:4536–4540.
  • Lu G, Wang L, Zhou A, et al. Epitope analysis, expression and protection of SAG5A vaccine against Toxoplasma gondii. Acta Trop. 2015;146:66–72.
  • Xu Y, Zhang NZ, Chen J, et al. Toxoplasma gondii rhoptry protein 38 gene sequence variation among isolates from different hosts and geographical locations. Genet Mol Res. 2014;13:4839–4844.
  • Peixoto L, Chen F, Harb OS, et al. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe. 2010;8:208–218.
  • Xu Y, Zhang NZ, Tan QD, et al. Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38). BMC Infect Dis. 2014;14:525.
  • Jongert E, Lemiere A, Van Ginderachter J, et al. Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Vaccine. 2010;28:2556–2564.
  • Qu D, Han J, Du A. Evaluation of protective effect of multiantigenic DNA vaccine encoding MIC3 and ROP18 antigen segments of toxoplasma gondii in mice. Parasitol Res. 2013;112:2593–2599.
  • Xenopoulos A, Pattnaik P. Production and purification of plasmid DNA vaccines: is there scope for further innovation? Expert Rev Vaccines. 2014;13:1537–1551.
  • Joyce BR, Queener SF, Wek RC, et al. Phosphorylation of eukaryotic initiation factor-2α promotes the extracellular survival of obligate intracellular parasite Toxoplasma gondii. Proc Natl Acad Sci USA. 2010;107:1720–1725.
  • Chen J, Huang SY, Zhou DH, et al. DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice. Vaccine. 2013;31:6225–6231.
  • Chen J, Fang SF, Zhou DH, et al. Protective immunity induced by a DNA vaccine expressing eIF4A of Toxoplasma gondii against acute toxoplasmosis in mice. Genet Mol Res. 2014;13:3356–3361.
  • Hassan IA, Wang S, Xu L, et al. DNA vaccination with a gene encoding Toxoplasma gondii deoxyribose phosphate aldolase (TgDPA) induces partial protective immunity against lethal challenge in mice. Parasit Vectors. 2014;7:431.
  • Moreno SN, Docampo R. Calcium regulation in protozoan parasites. Curr Opin Microbiol. 2003;6:359–364.
  • Zhang NZ, Huang SY, Zhou DH, et al. Protective immunity against Toxoplasma gondii induced by DNA immunization with the gene encoding a novel vaccine candidate: calcium-dependent protein kinase 3. BMC Infect Dis. 2013;13:512.
  • Chu D, Moroda M, Piao LX, et al. CTL induction by DNA vaccine with Toxoplasma gondii-HSP70 gene. Parasitol Int. 2014;63:408–416.
  • Zhang NZ, Huang SY, Xu Y, et al. Evaluation of immune responses in mice after DNA immunization with putative Toxoplasma gondii calcium-dependent protein kinase 5. Clin Vaccine Immunol. 2014;21:924–929.
  • Zhao G, Zhou A, Lu G, et al. Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis. Parasit Vectors. 2013;6:175.
  • Wang S, Hassan IA, Liu X, et al. Immunological changes induced by Toxoplasma gondii glutathione-S-transferase (TgGST) delivered as a DNA vaccine. Res Vet Sci. 2015;99:157–164.
  • Hassan IA, Wang S, Xu L, et al. Immunoglobulin and cytokine changes induced following immunization with a DNA vaccine encoding Toxoplasma gondii selenium-dependent glutathione reductase protein. Exp Parasitol. 2014;146:1–10.
  • Yin LT, Hao HX, Wang HL, et al. Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis. PLoS One. 2013;8:e82765.
  • Hassan IA, Wang S, Xu L, et al. Immunological response and protection of mice immunized with plasmid encoding Toxoplasma gondii glycolytic enzyme malate dehydrogenase. Parasite Immunol. 2014;36:674–683.
  • Zhang NZ, Xu Y, Wang M, et al. Protective efficacy of two novel DNA vaccines expressing Toxoplasma gondii rhomboid 4 and rhomboid 5 proteins against acute and chronic toxoplasmosis in mice. Expert Rev Vaccines. 2015;14:1289–1297.

* Immunization of both of pVAX-ROM4 and pVAX-ROM5 could trigger strong humoral and cellular responses, and elicit effective protective immunity against acute and chronic toxoplasmosis in mice. A better protective efficacy was detected in mice immunized with pVAX-ROM5

  • Zhao G, Zhou A, Lv G, et al. Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis. BMC Infect Dis. 2013;13:207.
  • Zhang TE, Yin LT, Li RH, et al. Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T-and B-cell epitopes via an intranasal route against toxoplasmosis in mice. Parasit Vectors. 2015;8:15.
  • Debierre-Grockiego F, Campos MA, Azzouz N, et al. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. J Immunol. 2007;179:1129–1137.
  • Yarovinsky F, Zhang D, Andersen JF, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science. 2005;308:1626–1629.
  • Sibley LD. Invasion and intracellular survival by protozoan parasites. Immunol Rev. 2011;240:72–91.
  • Sukhumavasi W, Egan CE, Warren AL, et al. TLR adaptor MyD88 is essential for pathogen control during oral Toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J Immunol. 2008;181:3464–3473.
  • Stevceva L. Toll-like receptor agonists as adjuvants for HIV vaccines. Curr Med Chem. 2011;18:5079–5082.
  • Sturge CR, Benson A, Raetz M, et al. TLR-independent neutrophil-derived IFN-γ is important for host resistance to intracellular pathogens. Proc Natl Acad Sci USA. 2013;110:10711–10716.
  • Bessieres MH, Swierczynski B, Cassaing S, et al. Role of IFN-gamma, TNF-alpha, IL-4 and IL-10 in the regulation of experimental Toxoplasma gondii infection. J Eukaryot Microbiol. 1997;44:87S.
  • Sa Q, Woodward J, Suzuki Y. IL-2 produced by CD8+ immune T cells can augment their IFN-γ production independently from their proliferation in the secondary response to an intracellular pathogen. J Immunol. 2013;190:2199–2207.
  • Chen G, Chen H, Guo H, et al. Protective effect of DNA-mediated immunization with a combination of SAG1 and IL-2 gene adjuvant against infection of Toxoplasma gondii in mice. Chin Med J (Engl). 2002;115:1448–1452.
  • Chen J, Li ZY, Huang SY, et al. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice. BMC Infect Dis. 2014;14:487.
  • Li ZY, Chen J, Petersen E, et al. Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice. Vaccine. 2014;32:3058–3065.
  • Sun X, Mei M, Zhang X, et al. The extracellular matrix protein mindin as a novel adjuvant elicits stronger immune responses for rBAG1, rSRS4 and rSRS9 antigens of Toxoplasma gondii in BALB/c mice. BMC Infect Dis. 2014;14:429.
  • Sánchez VR, Fenoy IM, Picchio MS, et al. Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection. Acta Trop. 2015;150:159–165.
  • Wagner A, Schabussova I, Ruttkowski B, et al. Prime-boost vaccination with Toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice. PLoS ONE. 2015;10:e0126334.
  • Tanaka S, Kuroda Y, Ihara F, et al. Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii. Vaccine. 2014;32:1781–1785.
  • Koblansky AA, Jankovic D, Oh H, et al. Recognition of profilin by toll-like receptor 12 is critical for host resistance to Toxoplasma gondii. Immunity. 2013;38:119–130.
  • Gong P, Huang X, Yu Q, et al. The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB/c mice. Parasite Immunol. 2013;35:140–146.
  • Yu Q, Huang X, Gong P, et al. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Vaccine. 2013;31:6065–6071.
  • Ibrahim HM, Bannai H, Xuan X, et al. Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces bradyzoite conversion in a CCR5-dependent manner. Infect Immun. 2009;77:3686–3695.
  • Chuang SC, Ko JC, Chen CP, et al. Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasit Vectors. 2013;6:34.
  • Xu Y, Zhang NZ, Wang M, et al. A longlasting protective immunity against chronic toxoplasmosis in mice induced by recombinant rhoptry proteins encapsulated in poly (lactide-co-glycolide) microparticles. Parasitol Res. 2015;114:4195–4203.
  • Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine. 2010;6:523–529.
  • Okamoto S, Matsuura M, Akagi T, et al. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine. 2009;27:5896–5905.
  • Debin A, Kravtzoff R, Santiago JV, et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine. 2002;20:2752–2763.
  • van Riet E, Ainai A, Suzuki T, et al. Combatting infectious diseases nanotechnology as a platform for rational vaccine design. Adv Drug Deliv Rev. 2014;4:28–34.
  • Cong H, Mui EJ, Witola WH, et al. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-gamma and reduces parasite burden in HLA-B*0702 mice. Hum Immunol. 2012;73:1–10.
  • Tan TG, Mui E, Cong H, et al. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine. 2010;28:3977–3989.
  • Sivakumar SM, Safhi MM, Kannadasan M, et al. Vaccine adjuvants current status and prospects on controlled release adjuvancity. Saudi Pharm J. 2011;19:197–206.
  • Leng J, Butcher BA, Denkers EY. Dysregulation of macrophage signal transduction by Toxoplasma gondii: past progress and recent advances. Parasite Immunol. 2009;31:717–728.
  • Henriquez FL, Woods S, Cong H, et al. Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol. 2010;26:550–555.
  • Torres-Morales E, Taborda L, Cardona N, et al. Th1 and Th2 immune response to P30 and ROP18 peptides in human toxoplasmosis. Med Microbiol Immunol. 2014;203:315–322.
  • Cong H, Mui EJ, Witola WH, et al. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8 T cell epitope based adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010;6:12.
  • Cong H, Mui EJ, Witola WH, et al. Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine. 2011;29:754–762.
  • Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol. 2011;23:377–382.

* This paper deals with human immune response to different peptides from virulent and nonvirulent strains and is a first demonstration of the ex vivo analysis to identify the protective (asymptomatic people) and sick people (immune response in people with different human disease forms)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.